Blossom covers the latest that goes on with psychedelic research. We make the waterfall of new papers easier to digest, for both laypeople, psychedelic entrepreneurs, and researchers alike. We provide handy overview posts every month and research highlights every second week.
Need an overview of where the research stands at this moment? Dive in with our Research Overview.
How can microdosing support people who experience ADHD, and does it work better than conventional medications? The first article explores this across two studies. We then venture into the heart of Europe, where psychedelic-assisted psychotherapy has been legally possible for the last decade (again). Finally, I'll focus on the flexible repeated dosing in a trial with psilocybin for depression.
January saw new psychedelic trials on ibogaine for TBI, DMT, and psilocybin for CCHs, alongside re-analyses on psychedelic brain impacts, therapy dynamics in MDMA treatment, and LSD visuals. Studies also probed SSRI-psychedelic interactions, expectancy roles, and heart effects from microdosing.
This is all the other psychedelic research that came out in December 2023. These papers don't (yet) have their own page in our database.
Blossom‘s articles cover everything from the latest paper (also featured individually in our Papers Database) to analyses of research fields. From MDMA-AT for PTSD to psilocybin for TRD. We will pick apart the industry terms, e.g. MDMA-AT = MDMA-assisted therapy